Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease

We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxom...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2000-09, Vol.19 (2), p.174-182
Main Authors: Torres, Juan M, Ramı́rez, Miguel A, Morales, Mónica, Bárcena, Juan, Vázquez, Belén, Espuña, Enric, Pagès-Manté, Albert, Sánchez-Vizcaı́no, José M
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Caliciviridae Infections - prevention & control
Female
Fundamental and applied biological sciences. Psychology
Hemorrhagic Disease Virus, Rabbit - immunology
Immunization
Immunosuppression
Microbiology
myxoma virus
Myxoma-RHDV
Myxomatosis, Infectious - prevention & control
Pregnancy
rabbit hemorrhagic disease
Rabbit hemorrhagic disease virus
Rabbits
Safety
Transmissible vaccine
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Vaccines, Synthetic - adverse effects
Viral Vaccines - adverse effects
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit haemorragic disease using a recombinant myxoma virus. J. Virol. 2000;74:1114–23]. Administration of the recombinant virus protects rabbits against lethal RHDV and MV challenges. Furthermore, the recombinant virus is capable of horizontal spreading promoting protection of contact animals, thus providing the opportunity to immunize wild rabbit populations. However, potential risks must be extensively evaluated before considering its field use. In this study several safety issues concerning the proposed vaccine have been evaluated under laboratory conditions. Results indicated that vaccine administration is safe even at a 100-fold overdose. No undesirable effects were detected upon administration to immunosuppressed or pregnant rabbits. The recombinant virus maintained its attenuated phenotype after 10 passages in vivo.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(00)00183-3